Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Hospitals lost money on telehealth with every payer type in 2025

Strata Decision Technology's Performance Trends report found telehealth encounters at U.S. hospitals rose 79% from January 2019 to January 2026, yet average total cost margins were negative for commercial, Medicare, Medicaid and self-pay patients in 2025. Adoption has outrun reimbursement. The gap lands on health systems that posted a 0.2% operating margin in April, according to Strata.

  • 01A negative total cost margin on telehealth across all four payer categories is now a national benchmark from a dataset covering more than 2,200 hospitals; a health system's own per-encounter virtual care margin can be measured against it.
  • 02Remote patient monitoring encounters grew nearly 4,000% since 2019 while reimbursement for the service is still maturing, so an RPM business case built on volume alone will miss the number that actually decides its viability.
  • 03The signal to watch is whether any single payer category shows a positive telehealth margin in Strata's next Performance Trends cut. As of the 2025 data, none did.

Sep 18, 2026

Most reprocessing audit gaps trace back to training, turnover and leadership

Most reprocessing audit gaps trace back to training, turnover and leadership

Joint Commission findings on its reprocessing standard point mostly to training, turnover, leadership and missing ownership, not sterilizers. CDC epidemiologists and a 2019 review add cleaning verification and manufacturer instructions as the steps to watch. Audit people and process steps as closely as the autoclave.

  • 01Of the Joint Commission's list of reasons hospitals miss reprocessing standard IC.02.02.01, at least eight concern people, priorities and management, so competency records and a named process owner belong in the audit as much as sterilizer logs.
  • 02A structured audit tool that scores compliance step by step, as a 2020 BMC Health Services Research study did across 189 reprocessing cycles, shows where training hours should go; the Nepal hospitals scored best on cleaning and storage and worse on the steps between.

Sep 14, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512